Clinical trial Recruiting at 5 sites Interventional Ages 18 to 90

High-flow nasal cannula versus home mechanical ventilation for COPD patients with persistent high carbon dioxide after an exacerbation

Official title: Respiratory Strategies in COPD Patients With Persistent Hypercapnia Following Exacerbation: A Multicenter, Non-inferiority, Randomized, Crossover Study

Run by IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT07065799 · Data updated 2026-11-12

This study tests whether using high-flow nasal cannula plus standard oxygen can lower CO2 as well as home mechanical ventilation plus standard oxygen in people with COPD who still have high CO2 after a severe flare.

Quick facts

Study typeInterventional
Ages18 Years to 90 Years
SexAll
Enrollment31 (estimated)
SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna
Academic / other
Locations5 sites (Arezzo and 4 other locations)
StatusRecruiting
StartedJune 30, 2024
Main results expectedDecember 2027
Study endsJanuary 2028
Registry record updatedJuly 15, 2025
Trial IDNCT07065799 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with COPD who remain hypercapnic (PaCO2 >53 mmHg) 2–4 weeks after a hypercapnic exacerbation requiring noninvasive ventilation, with pH >7.35 and chronic hypoxemia meeting the protocol thresholds, are the intended participants.

Probably not a fit

Patients with BMI >30 kg/m2, clinically significant obstructive sleep apnea, neuromuscular or chest wall disease, those already on home NIV/CPAP, or those who required intubation during the exacerbation are unlikely to benefit from this comparison.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, randomized crossover trial enrolls patients with COPD and persistent hypercapnia after a severe exacerbation and compares two home respiratory supports: high‑flow nasal cannula (NHF) plus standard oxygen and home mechanical ventilation (HMV) plus standard oxygen. Each participant receives both treatments for three months in randomized order with a seven‑day washout, so each patient serves as their own control. The primary outcome is change in arterial PaCO2 to test non‑inferiority of NHF versus HMV. Secondary outcomes include safety, tolerability, and clinical events over the total 25‑week treatment period.

Why it matters

Potential benefit: If successful, the study could provide a simpler, better‑tolerated home breathing option that lowers CO2 similarly to home mechanical ventilation.

How similar studies have gone: Home mechanical ventilation is an established treatment for chronic hypercapnia, while high‑flow nasal cannula has shown promising PaCO2 reductions in smaller studies, but direct non‑inferiority comparisons versus HMV are still limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥18 years
* Acquisition of informed consent form
* Patients with COPD
* Persistent hypercapnia (PaCO2 \>53 mmHg) 2-4 weeks after an acute hypercapnic exacerbation of COPD requiring NIV.
* pH value \>7.35.
* Chronic hypoxemia (PaO2 \<55mmHg or \<60mmHg if at least one of the following criteria is present: polycythemia, pulmonary hypertension or Chronic Pulmonary Heart Disease, \>30% of sleep time with SpO2 \< 90% measured with a pulse oximeter)

Exclusion Criteria:

* BMI \>30 kg/m2
* Clinically significant obstructive sleep apnea syndrome (patients in whom there was a clinical suspicion of OSA syndrome based on clinical review or overnight oximetry will go further testing with limited respiratory polygraphy)
* Neuromuscular or chest wall diseases
* Need for intubation and invasive mechanical ventilation during exacerbation
* Use of home non-invasive mechanical ventilation or CPAP
* Contraindications for NIV
* Presence of cognitive impairment that would prevent informed consent into the trial
* Patients with active and unstable coronary artery syndrome
* Patients suffering from malignancies

Where it's running

  • Ospedale S Donato
    Arezzo, Italy
    Recruiting
  • Bolzano Hospital
    Bolzano, Italy
    Recruiting
  • Azienda Ospedaliera Universitaria Policlinico "G. Rodolico-Sn Marco"
    Catania, Italy
    Recruiting
  • ICS Maugeri Spa Società Benefit IRCCS
    Pavia, Italy
    Recruiting
  • Azienda Unità Sanitaria Locale
    Piacenza, Italy
    Recruiting

Study contacts

  • Principal investigator: Lara Pisani, Prof.ssa — University of Bologna
  • Study coordinator: Lara Pisani, Prof.ssa
  • Email: lara.pisani@unibo.it
  • Phone: 0512143257

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.